Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) filed a Form 8-K on February 19, 2020, reporting the termination of a material definitive agreement. The company is a Delaware corporation headquartered in Bedminster, New Jersey.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data provided relates to a historical equity offering:
- Historical Offering Capacity: Up to $30.0 million under the terminated agreement.
- Shares Sold: 13,220,987 shares of Common Stock sold between August 2017 and October 2018.
Material Changes
The primary material change is the termination of the Controlled Equity Offering Sales Agreement dated April 28, 2017, with Cantor Fitzgerald & Co. The termination was effective on or before March 1, 2020. The company confirmed there are no termination penalties associated with this action.
Outlook, Risks, and Management Commentary
Management commentary is limited to the notification of the agreement's termination. No forward-looking guidance, risk factors, or contingencies specific to future operations were disclosed in this report. The filing indicates the company is no longer subject to the terms of the specific equity sales agreement with Cantor Fitzgerald.
Investor Verification Checklist
- Verify the effective date of the termination (on or before March 1, 2020).
- Confirm the absence of termination penalties or fees.
- Review the company's current capital raising strategy given the termination of the $30.0 million sales agreement.
- Check subsequent filings for any new equity distribution agreements.